Business Wire

Virtuozzo Reveals New Hybrid Cloud Solution, Designed Specifically for Managed and Cloud Service Providers

18.5.2021 11:00:00 EEST | Business Wire | Press release

Share

Virtuozzo, a global leader in high-efficiency virtualization and hyperconverged software solutions, has announced the availability of its newest product, Virtuozzo Hybrid Cloud. The solution enables Managed Service Providers (MSPs) and Cloud Service Providers (CSP) to design, build and sell modern cloud services to customers quickly and more cost-effectively than traditional hyperscalers.

The cloud infrastructure market continues to experience strong growth as businesses become increasingly more dependent on cloud-based resources. This evolution presents an opportunity for service providers to carve out an alternative to the often complex and expensive traditional cloud providers. According to Liam Eagle, Research Director, 451 Research, a part of S&P Global Market Intelligence, “As the breadth of organizations seeking cloud solutions continues to grow, a gap in the skills necessary to navigate the complexities of the most advanced cloud platforms is a common limitation. This presents an opportunity for the alternative vendors to solidify the role of their services as delivering the core value proposition of cloud in a simpler, more digestible and often lower-cost configuration.” 1

Virtuozzo Hybrid Cloud was created to help service providers address this demand. The company’s new product offers MSPs and CSPs an alternative, fully managed cloud solution that ensures clear SLAs and 24/7 production support, allowing service providers to focus on value-added services and project development rather than infrastructure maintenance and management.

Virtuozzo Hybrid Cloud is one of the only hybrid cloud solutions exclusively for MSPs and CSPs. It offers Infrastructure as a Service (IaaS), Platform as a Service (PaaS), Load Balancer as a Service (LBaaS), Storage as a Service (SaaS), and other cloud services in multiple locations worldwide.

Service providers can buy cloud resources directly from Virtuozzo by connecting any Open Stack compatible cloud management platform such as CloudBlue Connect, HostBill, WHMCS, Fleio, or from Virtuozzo Hybrid Cloud distributors.

“Over the past year and a half, we have seen a lot of demand from our existing service provider partners for a solution that enables them to offer infrastructure solutions. We designed Virtuozzo Hybrid Cloud to address this need while offering more than 30% savings over comparable solutions. We are thrilled to bring a turnkey solution to the market that helps MSPs and CSPs open new opportunities and drive customer growth for years to come. We are excited to innovate and grow together with our partners,” remarks Ahmed Amni, Director of Sales, EMEA.

Virtuozzo Hybrid Cloud is built on Virtuozzo Hybrid Infrastructure, a best-in-class hyperconverged infrastructure (HCI) solution. Virtuozzo Hybrid Infrastructure provides service providers with cost-effective, easy-to-manage hyperconverged infrastructure that optimizes hardware utilization, lowers total cost of ownership, and delivers high server performance and availability. Secure by design, Virtuozzo Hybrid Infrastructure combines compute, storage, and networking services with advanced analytics and monitoring in a single, hardware-agnostic solution.

Virtuozzo Hybrid Cloud is available to service providers throughout Europe today, with global availability rolling out quickly. Pricing is based on either a Pay-as-You-Go model or on a reservation-based model, which extends additional cost savings to partners. To learn more about partnership opportunities or to view a product demo visit the company’s website.

About Virtuozzo

Virtuozzo is a leading, global provider of hybrid virtualization, storage and cloud enablement software solutions. The company’s software-defined, hyperconverged self-service platform and resource management capabilities enable hosting and service providers to provide end-customers with public and private cloud services. Virtuozzo is an industry pioneer who developed the first commercially available container technology 21 years ago. The company provides software solutions and services to over 450 service providers, ISVs, and enterprises worldwide to enable over 500 thousand virtual environments, running mission-critical cloud workloads. A significant force in the opensource community, Virtuozzo sponsors and/or is a contributor to numerous open-source projects including KVM, Docker, OpenStack, OpenVZ, CRIU and the Linux kernel. Learn more www.virtuozzo.com.

1 451 Research, Demand and opportunity in the alternative cloud provider market, January 2021

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Heather Ailara
211 Communications
+1.973.567.6040
heather@211comms.com

Christine Brunelli
Virtuozzo
+1 215-847-7842
christine.brunelli@virtuozzo.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release

IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye